Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation
Douglas D. Fang(Pfizer (United States)), Todd VanArsdale(Pfizer (United States))
Cited by 44
Related Papers
Activating <i>JAK1</i> mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma
|Oncotarget|2015|49
Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models
|BMC Cancer|2022|31
PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib
|Scientific Reports|2022|14